ACADIA PHARMACEUTICALS INC — Director's Dealing 2019

Dec 13, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2019-12-11

Reporting Person: KIM AUSTIN D. (EVP & General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-11	Common Stock	M	17500	$17.58	Acquired	18009	Direct
2019-12-11	Common Stock	S	17500	$45.0615	Disposed	509	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-11	Stock Option (Right to Buy)	$17.58	M	17500	Disposed	2028-07-17	Common Stock (17500)	Direct

Footnotes

F1: Includes 452 shares of the Issuer's common stock acquired by the reporting person on May 15, 2019 and 57 shares of the Issuer's common stock acquired by the reporting person on November 15, 2019 pursuant to an employee stock purchase program.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.215, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3: 25% of the 140,000 shares originally subject to the stock option vested and became exercisable on July 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.